Management of the elderly patients with inflammatory bowel disease: Practical considerations

Seymour Katz, Christina Surawicz, Darrell S. Pardi

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The aging U.S. population will approach 20% of the total population by 2030. The number of older patients with inflammatory bowel disease is anticipated to increase accordingly bringing the burden of multiple comorbidities, polypharmacy with drug interactions, the aging immune system, and extended social and financial issues to overall management of an already challenging management of these patients. Each of these concerns is measured by the metric of distinguishing the "fit versus frail" elderly and will be discussed in this review with an emphasis on a practical guide to therapy.

Original languageEnglish (US)
Pages (from-to)2257-2272
Number of pages16
JournalInflammatory Bowel Diseases
Volume19
Issue number10
DOIs
StatePublished - Sep 2013

Fingerprint

Inflammatory Bowel Diseases
Frail Elderly
Polypharmacy
Drug Interactions
Population
Comorbidity
Immune System
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Management of the elderly patients with inflammatory bowel disease : Practical considerations. / Katz, Seymour; Surawicz, Christina; Pardi, Darrell S.

In: Inflammatory Bowel Diseases, Vol. 19, No. 10, 09.2013, p. 2257-2272.

Research output: Contribution to journalArticle

Katz, Seymour ; Surawicz, Christina ; Pardi, Darrell S. / Management of the elderly patients with inflammatory bowel disease : Practical considerations. In: Inflammatory Bowel Diseases. 2013 ; Vol. 19, No. 10. pp. 2257-2272.
@article{4f5f802a3ef34cb89be735a3eead68c3,
title = "Management of the elderly patients with inflammatory bowel disease: Practical considerations",
abstract = "The aging U.S. population will approach 20{\%} of the total population by 2030. The number of older patients with inflammatory bowel disease is anticipated to increase accordingly bringing the burden of multiple comorbidities, polypharmacy with drug interactions, the aging immune system, and extended social and financial issues to overall management of an already challenging management of these patients. Each of these concerns is measured by the metric of distinguishing the {"}fit versus frail{"} elderly and will be discussed in this review with an emphasis on a practical guide to therapy.",
author = "Seymour Katz and Christina Surawicz and Pardi, {Darrell S.}",
year = "2013",
month = "9",
doi = "10.1097/MIB.0b013e31828c8536",
language = "English (US)",
volume = "19",
pages = "2257--2272",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Management of the elderly patients with inflammatory bowel disease

T2 - Practical considerations

AU - Katz, Seymour

AU - Surawicz, Christina

AU - Pardi, Darrell S.

PY - 2013/9

Y1 - 2013/9

N2 - The aging U.S. population will approach 20% of the total population by 2030. The number of older patients with inflammatory bowel disease is anticipated to increase accordingly bringing the burden of multiple comorbidities, polypharmacy with drug interactions, the aging immune system, and extended social and financial issues to overall management of an already challenging management of these patients. Each of these concerns is measured by the metric of distinguishing the "fit versus frail" elderly and will be discussed in this review with an emphasis on a practical guide to therapy.

AB - The aging U.S. population will approach 20% of the total population by 2030. The number of older patients with inflammatory bowel disease is anticipated to increase accordingly bringing the burden of multiple comorbidities, polypharmacy with drug interactions, the aging immune system, and extended social and financial issues to overall management of an already challenging management of these patients. Each of these concerns is measured by the metric of distinguishing the "fit versus frail" elderly and will be discussed in this review with an emphasis on a practical guide to therapy.

UR - http://www.scopus.com/inward/record.url?scp=84884550493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884550493&partnerID=8YFLogxK

U2 - 10.1097/MIB.0b013e31828c8536

DO - 10.1097/MIB.0b013e31828c8536

M3 - Article

C2 - 23860566

AN - SCOPUS:84884550493

VL - 19

SP - 2257

EP - 2272

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -